- Home
- CRIS vs BJDX Comparison
CRIS vs BJDX Comparison
Compare CRIS & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | BJDX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.1K | 865.6K |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRIS | BJDX |
|---|---|---|
| Price | $0.66 | $2.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 75.1K |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | 86.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | $249,040.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.33 | $0.46 |
| 52 Week High | $2,880.00 | $30.52 |
Technical Indicators
Market Signals| Indicator | CRIS | BJDX |
|---|---|---|
| Relative Strength Index (RSI) | 32.31 | 86.69 |
| Support Level | $0.33 | $0.78 |
| Resistance Level | $5.55 | $4.19 |
| Average True Range (ATR) | 0.21 | 0.83 |
| MACD | 0.32 | 0.21 |
| Stochastic Oscillator | 23.39 | 20.82 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.